常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
22.95/40.70
|
|
企業價值
925.23B
|
| 資產負債 |
|
每股賬面淨值
29.71
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
65.18B
|
|
每股收益
35.92
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltzand Olumiant for immunology. |

1,008.39 
